Desloratadine for allergic rhinitis.

[en] Seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR) affect up to 40% of the population (depending on geographical area), and are associated with significant morbidity, socioeconomic costs and reductions in quality of life. Antihistamines are a first-line therapy, with newer nonsedating agents having superseded sedating first-generation drugs. Desloratadine is a nonsedating, nonimpairing antihistamine that is effective in relieving nasal and non-nasal symptoms of SAR and PAR, including nasal congestion. Desloratadine has a 24-h duration of action, enabling once-daily dosing and providing relief of morning symptoms. Clinical trials have demonstrated that it has no performance impairment, cardiovascular effects or clinically relevant interactions with other tested medications. This article reviews the use of desloratadine in the treatment of SAR and PAR.

Disciplines :

Immunology & infectious disease

Author, co-author :

Wilken, Jeffrey A.

Daly, Adrian ; Université de Liège - ULiège > Département des sciences cliniques > Endocrinologie

Sullivan, Cynthia L.

Kim, Harold

Language :

English

Title :

Desloratadine for allergic rhinitis.

Publication date :

2006

Journal title :

Expert Review of Clinical Immunology

ISSN :

1744-666X

eISSN :

1744-8409

Publisher :

Taylor & Francis, United Kingdom

Volume :

Issue :

Pages :

209-24

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 30 August 2013

Statistics

Number of views

38 (0 by ULiège)

Number of downloads

0 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

van Cauwenberge P, Bachert C, Passalacqua G et al. Consensus statement on the treatment of allergic rhinitis. European Academy of Allergology and Clinical Immunology. Allergy 55(2), 116-134 (2000).
Skoner DP. Allergic rhinitis: definition, epidemiology, pathophysiology, detection, and diagnosis. J. Allergy Clin. Immunol. 108(Suppl. 1), S2-S8 (2001).
Bachert C, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. In collaboration with the World Health Organization. Executive summary of the workshop report. 7-10 December 1999, Geneva, Switzerland. Allergy 57(9), 841-855 (2002). Erratum in: Allergy 57 (12), 1208 (2002). Bousquet J [corrected to Bachert C].
Salib RJ, Drake-Lee A, Howarth PH. Allergic rhinitis: past, present and the future. Clin. Otolaryngol. Allied Sci. 28(4), 291-303 (2003).
Bronsky E. The burden of allergic disease. Patient Care 1-6 (2002).
Bauchau V, Durham SR. Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur. Respir. J. 24(5), 758-764 (2004).
Brunton SA. Allergy management strategies: an update. Patient Care. 16-25 (2002).
Reed SD, Lee TA, McCrory DC. The economic burden of allergic rhinitis: a critical evaluation of the literature. Pharmacoeconomics 22(6), 345-361 (2004).
Anderson L, Morath R, Light E, Wilken JA. Estimating the dollar utility of changes in job performance due to seasonal allergic rhinitis and its treatment. Human Performance 17(1), 43-69 (2004).
Blaiss M. Current concepts and therapeutic strategies for allergic rhinitis in school-age children. Clin. Ther. 26(11), 1876-1889 (2004).
Wilken JA, Berkowitz R, Kane R. Decrements in vigilance and cognitive functioning associated with ragweed-induced allergic rhinitis. Ann. Allergy Asthma Immunol. 89(4), 372-380 (2002).
Schoenwetter WF, Dupclay L Jr., Appajosyula S, Botteman MF, Pashos CL. Economic impact and quality-of-life burden of allergic rhinitis. Curr. Med. Res. Opin. 20(3), 305-317 (2004).
Welch MJ, Meltzer EO, Simons FE. H1-antihistamines and the central nervous system. Clin. Allergy Immunol. 17, 337-388 (2002).
Simons FE. Advances in H1-antihistamines. N. Engl. J. Med. 351(21), 2203-2217 (2004).
Schering Plough. Clarinex® (desloratadine) product information. Schering Plough, Kenilworth, NJ, USA (2004).
DuBuske LM. Pharmacology of desloratadine: special characteristics. Clin. Drug Invest. 22 (Suppl. 2), 1-11 (2002).
Ghosal A, Yuan Y, Hapangama N et al. Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of 3-hydroxydesloratadine. Biopharm. Drug Dispos. 25(6), 243-252 (2004).
Bachert C. Therapeutic points of intervention and clinical implications: role of desloratadine. Allergy 57(Suppl 75), 13-18 (2002).
Agrawal DK. Anti-inflammatory properties of desloratadine. Clin. Exp Allergy. 34(9), 1342-1348 (2004).
Wu RL, Anthes JC, Kreutner W, Harris AG, West RE Jr. Desloratadine inhibits constitutive and histamine-stimulated nuclear factor-κB activity consistent with inverse agonism at the histamine H1 receptor. Int. Arch. Allergy Immunol. 135(4), 313-318 (2004).
Anthes JC, Gilchrest H, Richard C et al. Biochemical characterization of desloratadine, a potent antagonist of the human histamine H(1) receptor. Eur. J. Pharmacol. 449(3), 229-237 (2002).
Kreutner W, Hey JA, Anthes J, Barnett A, Young S, Tozzi S. Preclinical pharmacology of desloratadine, a selective and nonsedating histamine H1 receptor antagonist. 1st communication: receptor selectivity, antihistaminic activity, and antiallergenic effects. Arzneimittelforschung 50(4), 345-352 (2000).
Kreutner W, Hey JA, Chiu P, Barnett A. Preclinical pharmacology of desloratadine, a selective and nonsedating histamine H1 receptor antagonist. 2nd communication: lack of central nervous system and cardiovascular effects. Arzneimittelforschung 50(5), 441-448 (2000).
Wilken JA, Kane RL, Ellis AK et al. A comparison of the effect of diphenhydramine and desloratadine on vigilance and cognitive function during treatment of ragweed-induced allergic rhinitis. Ann. Allergy Asthma Immunol. 91(4), 375-385 (2003).
Marino M, Glue P, Herron JM. Lack of electrocardiographic effects of multiple high doses of desloratadine. Allergy 55(Suppl. 63), 279 (2000).
Meltzer EO, Prenner BM, Nayak A, the Desloratadine Study Group. Efficacy and tolerability of once-daily 5mg desloratadine, an H1-receptor antagonist, in patients with seasonal allergic rhinitis assessment during the spring and fall allergy seasons. Clin. Drug Invest. 21(1), 25-32 (2001).
Affrime M, Gupta S, Banfield C, Cohen A. A pharmacokinetic profile of desloratadine in healthy adults, including elderly. Clin. Pharmacokinet. 41(Suppl. 1), 13-19 (2002).
Salmun LM, Lorber R. 24-hour efficacy of once-daily desloratadine therapy in patients with seasonal allergic rhinitis [ISRCTN32042139]. BMC Fam. Pract. 3, 14 (2002).
Gupta S, Banfield C, Affrime M et al. Desloratadine demonstrates dose proportionality in healthy adults after single doses. Clin. Pharmacokinet. 41(Suppl. 1), 1-6 (2002).
Affrime M, Banfield C, Gupta S et al. Effect of race and sex on single and multiple dose pharmacokinetics of desloratadine. Clin. Pharmacokinet. 41(Suppl 1), 21-28 (2002).
Gupta S, Banfield C, Affrime M, Marbury T, Padhi D, Glue P. Oral bioavailability of desloratadine is unaffected by food. Clin. Pharmacokinet. 41(Suppl 1), 7-12 (2002).
Banfield C, Gupta S, Marino M, Lim J, Affrime M. Grapefruit juice reduces the oral bioavailability of fexofenadine but not desloratadine. Clin. Pharmacokinet. 41(4), 311-318 (2002).
Barecki ME, Casciano CN, Johnson WW, Clement RP. In vitro characterization of the inhibition profile of loratadine, desloratadine, and 3-OH-desloratadine for five human cytochrome P-450 enzymes. Drug Metab. Dispos. 29(9), 1173-1175 (2001).
Wang EJ, Casciano CN, Clement RP, Johnson WW. Evaluation of the interaction of loratadine and desloratadine with P-glycoprotein. Drug Metab. Dispos. 29(8), 1080-1083 (2001).
Gupta S, Banfield C, Kantesaria B, Flannery B, Herron J. Pharmacokinetics/pharmacodynamics of desloratadine and fluoxetine in healthy volunteers. J. Clin. Pharmacol. 44(11), 1252-1259 (2004).
Gupta S, Banfield C, Kantesaria B et al. Pharmacokinetic and safety profile of desloratadine and fexofenadine when coadministered with azithromycin: a randomized, placebo-controlled, parallel-group study. Clin. Ther. 23(3), 451-466 (2001).
Banfield C, Herron J, Keung A, Padhi D, Affrime M. Desloratadine has no clinically relevant electrocardiographic or pharmacodynamic interactions with ketoconazole. Clin. Pharmacokinet. 41(Suppl 1), 37-44 (2002).
Banfield C, Hunt T, Reyderman L, Statkevich P, Padhi D, Affrime M. Lack of clinically relevant interaction between desloratadine and erythromycin. Clin. Pharmacokinet. 41(Suppl. 1), 29-35 (2002).
Khalilieh S, Krishna G, Marino M et al. Lack of interaction with coadministration of desloratadine and cimetidine. Ann. Allergy Asthma Immunol. 88, 110 (2002).
Dresser GK, Bailey DG, Leake BF et al. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin. Pharmacol. Ther. 71(1), 11-20 (2002).
Kleine-Tebbe J, Josties C, Frank G et al. Inhibition of IgE- and non-IgE-mediated histamine release from human basophil leukocytes in vitro by a histamine H1-antagonist, desethoxycarbonyl-loratadine. J. Allergy Clin. Immunol. 93(2), 494-500 (1994).
Kowalski ML, Lewandowska A, Wozniak J, Makowska J, Jankowski A, DuBuske L. Inhibition of nasal polyp mast cell and eosinophil activation by desloratadine. Allergy 60(1), 80-85 (2005).
Wang YH, Tache Y, Harris AG, Kreutner W, Daly AF, Wei JY. Desloratadine prevents compound 48/80-induced mast cell degranulation: visualization using a vital fluorescent dye technique. Allergy 60(1), 117-124 (2005).
Molet S, Gosset P, Lassalle P, Czarlewski W, Tonnel AB. Inhibitory activity of loratadine and descarboxyethoxyloratadine on histamine-induced activation of endothelial cells. Clin. Exp Allergy. 27(10), 1167-1174 (1997).
Schroeder JT, Schleimer RP, Lichtenstein LM, Kreutner W. Inhibition of cytokine generation and mediator release by human basophils treated with desloratadine. Clin. Exp Allergy 31(9), 1369-1377 (2001).
Greiff L, Persson CG, Andersson M. Desloratadine reduces allergen challenge-induced mucinous secretion and plasma exudation in allergic rhinitis. Ann. Allergy Asthma Immunol. 89(4), 413-418 (2002).
Horak F, Stubner UP, Zieglmayer R, Harris AG. Effect of desloratadine versus placebo on nasal airflow and subjective measures of nasal obstruction in subjects with grass pollen-induced allergic rhinitis in an allergen-exposure unit. J. Allergy Clin. Immunol. 109(6), 956-961 (2002).
Horak F, Stubner P, Zieglmeyer R, Harris AG. Comparison of the effects of desloratadine 5-mg daily and placebo on nasal airflow and seasonal allergic rhinitis symptoms induced by grass pollen exposure. Allergy 58(6), 481-485 (2003).
Horak F, Stubner P. Decongestant activity of desloratadine in controlled allergen-exposure trials. Clin. Drug Invest. 22(Suppl. 2), 13-20 (2002).
Lee DK, Haggart K, Currie GP, Anderson SD, Lipworth BJ. The effects of histamine and leukotriene receptor antagonism on nasal mannitol challenge in allergic rhinitis. Br. J. Clin. Pharmacol. 55(6), 639-642 (2003). Erratum in: Br. J. Pharmacol. 57(2), 227 (2004).
Lee DK, Gardiner M, Haggart K, Fujihara S, Lipworth BJ. Comparative effects of desloratadine, fexofenadine, and levocetirizine on nasal adenosine monophosphate challenge in patients with perennial allergic rhinitis. Clin. Exp Allergy. 34(4), 650-653 (2004).
Passalacqua G, Guerra L, Compalati E et al. Comparison of the effects in the nose and skin of a single dose of desloratadine and levocetirizine over 24 hours. Int. Arch. Allergy Immunol. 135(2), 143-147 (2004).
Haye R, Høye K, Berg O, Frønes S, Ødegård T. Morning versus evening dosing of desloratadine in seasonal allergic rhinitis: a randomized controlled study [ISRCTN23032971]. Clin. Mol. Allergy. 3, 3(2005).
Berger WE, Schenkel EJ, Mansfield LE, the Desloratadine Study Group. Safety and efficacy of desloratadine 5 mg in asthma patients with seasonal allergic rhinitis and nasal congestion. Ann. Allergy Asthma Immunol. 89(5), 485-491 (2002).
Rossi GA, Tosca MA, Passalacqua G, Bianchi B, Le Grazie C, Canonica GW. Evidence of desloratadine syrup efficacy and tolerability in children with pollen-induced allergic rhinitis. Allergy 60(3), 416-417 (2005).
Simons FE, Prenner BM, Finn A Jr, the Desloratadine Study Group. Efficacy and safety of desloratadine in the treatment of perennial allergic rhinitis. J. Allergy Clin. Immunol. 111(3), 617-622 (2003).
Kim KT, Sussman GL, Herbert J et al. Effect of once-daily desloratadine in patients with perennial allergic rhinitis (PAR): a double-blind, placebo-controlled study. J. Allergy Clin. Immunol. 111, S76-S77 (2003) (Abstract 25).
Holmberg K, Tonnel AB, Dreyfus I, Gustafsson E. Desloratadine reduces nasal congestion in persistent (perennial) allergic rhinitis. Proceedings of the XXIII EAACI Congress. Amsterdam, The Netherlands, p.84. Abstract 261 and poster (2004).
Nayak AS, Schenkel E. Desloratadine reduces nasal congestion in patients with intermittent allergic rhinitis. Allergy 56(11), 1077-1080 (2001).
Wilson AM, Haggart K, Sims EJ, Lipworth BJ. Effects of fexofenadine and desloratadine on subjective and objective measures of nasal congestion in seasonal allergic rhinitis. Clin. Exp Allergy. 32(10), 1504-1509 (2002).
Bhatia S, Baroody FM, deTineo M, Naclerio RM. Increased nasal airflow with budesonide compared with desloratadine during the allergy season. Arch. Otolaryngol. Head Neck Surg. 131(3), 223-228 (2005).
Schenkel E, Corren J, Murray JJ. Efficacy of once-daily desloratadine/ pseudoephedrine for relief of nasal congestion. Allergy Asthma Proc. 23(5), 325-330 (2002).
Pleskow W, Grubbe R, Weiss S, Lutsky B. Efficacy and safety of an extended-release formulation of desloratadine and pseudoephedrine vs the individual components in the treatment of seasonal allergic rhinitis. Ann. Allergy Asthma Immunol. 94(3), 348-354 (2005).
Ciprandi G, Tosca MA, Milanese M, Schenone G, Ricca V. Antihistamines added to an antileukotriene in treating seasonal allergic rhinitis: histamine and leukotriene antagonism. Allerg. Immunol. (Paris) 36(2), 67-70, 72 (2004).
Baena-Cagnani CE, Berger WE, DuBuske LM et al. Comparative effects of desloratadine versus montelukast on asthma symptoms and use of β2-agonists in patients with seasonal allergic rhinitis and asthma. Int. Arch. Allergy Immunol. 130(4), 307-313 (2003).
Bachert C, Virchow JC, Plenker A. Desloratadine in the treatment of seasonal allergic rhinitis: results of a large observational study. Clin. Drug Invest. 22(Suppl. 2), 43-52 (2002).
Kerney D. Real world treatment with desloratadine in seasonal allergic rhinitis (SAR) patients. Ann. Allergy Asthma Immunol. 90, 123 (2003).
Glass DJ, Harper AS. Assessing satisfaction with desloratadine and fexofenadine in allergy patients who report dissatisfaction with loratadine. BMC Fam. Pract. 4, 10 (2003).
Glass D, Harper A. Assessing patient satisfaction with desloratadine after conversion from loratadine, fexofenadine, or cetirizine. Manag. Care Interface 17(2), 29-34 (2004).
Tonnel AB, Holmberg K, Sauvage N, Enander I. Desloratadine improves the health-related quality of life in persistent allergic rhinitis. Proceedings of the XXIII EAACI Congress. Amsterdam, The Netherlands, p.84. Abstract 260 and poster (2004).
Day JH, Briscoe MP, Rafeiro E, Ratz JD. Comparative clinical efficacy, onset and duration of action of levocetirizine and desloratadine for symptoms of seasonal allergic rhinitis in subjects evaluated in the Environmental Exposure Unit (EEU). Int. J. Clin. Pract. 58(2), 109-118 (2004).
Geha RS, Meltzer EO. Desloratadine: A new, nonsedating, oral antihistamine. J. Allergy Clin. Immunol. 107(4), 751-762 (2001).
Vuurman EF, Rikken GH, Muntjewerff ND, de Halleux F, Ramaekers JG. Effects of desloratadine, diphenhydramine, and placebo on driving performance and psychomotor performance measurements. Eur. J. Clin. Pharmacol. 60(5), 307-313 (2004).
Valk PJ, Van Roon DB, Simons RM, Rikken G. Desloratadine shows no effect on performance during 6 h at 8,000 ft simulated cabin altitude. Aviat. Space Environ. Med. 75(5), 433-438 (2004).
Nicholson AN, Handford AD, Turner C, Stone BM. Studies on performance and sleepiness with the H-1-antihistamine, desloratadine. Aviat. Space Environ. Med. 74(8), 809-815 (2003).
Satish U, Streufert S, Dewan M, Voort SV. Improvements in simulated real-world relevant performance for patients with seasonal allergic rhinitis: impact of desloratadine. Allergy 59(4), 415-420 (2004).
Bloom M, Staudinger H, Herron J. Safety of desloratadine syrup in children. Curr. Med. Res. Opin. 20(12), 1959-1965 (2004).
Bousquet J, Bindslev-Jensen C, Canonica GW et al. The ARIA/EAACI criteria for antihistamines: an assessment of the efficacy, safety and pharmacology of desloratadine. Allergy 59(Suppl. 77), 4-16 (2004).